Evidence map›Paper›PMID 39149248›Full record

ArticlebioRxiv : the preprint server for biology2024

Deciphering tumour microenvironment and elucidating the origin of cancer cells in ovarian clear cell carcinoma.

Uma S Kamaraj, Pradeep Gautam, Terence Cheng, Tham Su Chin, Sun Kuie Tay, Tew Hong Ho, Ravichandran Nadarajah, Ronald Chin Hong Goh, Shing Lih Wong, Sangeeta Mantoo and 6 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Uma S KamarajInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore.ORCID 0000-0002-3378-2219
Pradeep GautamInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore.ORCID 0000-0002-3689-8380
Terence ChengInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore.
Tham Su ChinInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore.
Sun Kuie TayDepartment of Obstetrics & Gynaecology, Singapore General Hospital, Outram Road, Singapore 169608.
Tew Hong HoDepartment of Obstetrics & Gynaecology, Singapore General Hospital, Outram Road, Singapore 169608.
Ravichandran NadarajahDepartment of Obstetrics & Gynaecology, Singapore General Hospital, Outram Road, Singapore 169608.
Ronald Chin Hong GohDepartment of Anatomical Pathology, Singapore General Hospital, Academia, College Road, Singapore 169856.
Shing Lih WongDepartment of Anatomical Pathology, Singapore General Hospital, Academia, College Road, Singapore 169856.
Sangeeta MantooDepartment of Anatomical Pathology, Singapore General Hospital, Academia, College Road, Singapore 169856.
Inny BusmanisDepartment of Anatomical Pathology, Singapore General Hospital, Academia, College Road, Singapore 169856.
Hu LiCenter for Individualized Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Minh Tn LeYong Loo Lin School of Medicine, National University of Singapore, Singapore.
Qi-Jing LiInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore.
Elaine Hsuen LimDivision of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583.
Yuin-Han LohInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in ADR01AG061796 · NIA · MAYO CLINIC JACKSONVILLE · PI ERTEKIN-TANER, NILUFER · 2018 to 2022
$5.7M
Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteinsRF1AG056318 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LI, HU, WOLOZIN, BENJAMIN L · 2018 to 2020
$4.4M
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasisR01CA240323 · NCI · MAYO CLINIC ROCHESTER · PI ZHU, SHIZHEN · 2020 to 2024
$1.8M
Uncovering therapeutic-associated biomarkers via machine learning and feature engineering approachesR03OD034496 · OD · MAYO CLINIC ROCHESTER · PI LI, HU · 2022 to 2022
$318k
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA240323NIA NIH HHS R01 AG061796NIA NIH HHS RF1 AG056318NIH HHS R03 OD034496
6 · The paper itself

Abstract

Ovarian clear cell carcinoma (CCC) has an East Asian preponderance. It is associated with endometriosis, a benign condition where endometrial (inner lining of the uterus) tissue is found outside the uterus and on the peritoneal surface, in the abdominal or pelvic space. CCC is relatively more resistant to conventional chemotherapy compared to other ovarian cancer subtypes and is associated with a poorer prognosis. In this study, we recruited and obtained tumour tissues from seven patients across the four stages of CCC. The tumour and the tumour microenvironment (TME) from 7 CCC patients spanning clinical stages 1-4 were transcriptionally profiled using high-resolution scRNA-seq to gain insight into CCC's biological mechanisms. Firstly, we built a scRNA-seq resource for the CCC tumour microenvironment (TME). Secondly, we identified the different cell type proportions and found high levels of immune infiltration in CCC. Thirdly, since CCC is associated with endometriosis, we compared CCC with two publicly available endometriosis scRNA-seq datasets. The CCC malignant cells showed similarities with glandular secretory and ciliated epithelial cells found in endometriosis. Finally, we determined the differences in cell-cell communication between various cell types present in CCC TME and endometriosis conditions to gain insights into the transformations in CCC.

Identifiers

PMID39149248
PMCPMC11326226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.